Pharmaceutical

AlveoGene Launches to Develop Unique Inhaled Gene Therapies for Rare Respiratory Disorders

New gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership…

10 months ago

Intravacc Announces Review Publication of OMV-based Intranasal Vaccines for Disease Prevention

Intravacc - intranasally administered OMV Key mode of action of intranasally administered OMVs. Mucosal route induces both localized and systemic…

10 months ago

Pharmazz Inc. and Sun Pharma enter into licensing agreement for introducing Tyvalzi™ (Sovateltide) in India

Sovateltide is a first of its kind drug to treat acute cerebral ischemic stroke that can be administered up to…

10 months ago

Novo Integrated Sciences’ IoNovo for Kids Granted Registration Number and Regulatory Approval by Turkey’s Ministry of Health

Partners with NOYEM Global Foreign Trade and Consultancy Inc. for Distribution in TurkeyBELLEVUE, Wash.--(BUSINESS WIRE)--$NVOS #AAPI--Novo Integrated Sciences, Inc. (NASDAQ:…

10 months ago

Patent Issued in Japan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

New patent issued to Napo Pharmaceuticals, a Jaguar Health family company, for core rare disease target indication for crofelemerJaguar is…

10 months ago

Cosmos Health Starts Stock Buyback Program

CHICAGO, IL / ACCESSWIRE / September 13, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

10 months ago

Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of ImotopeTM IMCY-0141 for the Treatment of Multiple Sclerosis 

LIEGE, BELGIUM / ACCESSWIRE / September 13, 2023 / Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new…

10 months ago

Aytu BioPharma to Present at LD Micro Main Event XVI Conference

ENGLEWOOD, CO / ACCESSWIRE / September 13, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company…

10 months ago

Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease

Company's flu vaccine, mRNA-1010, met its primary endpoint in Phase 3 trial; separate Phase 1/2 data demonstrated higher HAI titers…

10 months ago